Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal

Annals of oncology : official journal of the European Society for Medical Oncology

Volumn 28, Issue 5, 2017, Pages 1036-1041

  Ott, P A ^a   Piha Paul, S A ^a   Munster, P ^a   Pishvaian, M J ^a   van Brummelen, E M J ^a   Cohen, R B ^a   Gomez Roca, C ^a   Ejadi, S ^a   Stein, M ^a   Chan, E ^a   Simonelli, M ^a   Morosky, A ^a   Saraf, S ^a   Emancipator, K ^a   Koshiji, M ^a   Bennouna, J ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

immunotherapy; KEYNOTE 028; PD 1; PD L1; pembrolizumab; squamous cell advanced anal carcinoma

Indexed keywords

IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PEMBROLIZUMAB;

AGED; ANAL CANAL; ANUS TUMOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PHASE 1 CLINICAL TRIAL; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANAL CANAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME;

EID: 85026837838     PISSN: None     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx029     Document Type: Article

References (0)